|
|
|
|
|
|
Sponsored by: |
EMD Serono |
Information provided by: | EMD Serono |
ClinicalTrials.gov Identifier: | NCT00619307 |
To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44mcg three-times-weekly) to the new formulation of Rebif while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurance of flu-like symptoms.
Condition | Intervention | Phase |
Relapsing Multiple Sclerosis |
Drug: Rebif New Formulation + prophylactically Ibuprofen Drug: Rebif New Formulation + ibuprofen PRN |
Phase III |
MedlinePlus related topics: | Flu Multiple Sclerosis |
ChemIDplus related topics: | Ibuprofen Dexibuprofen Interferon alfa-2b Interferons Interferon beta Interferon-beta Interferon beta 1a |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Open Label, Parallel Assignment |
Official Title: | A Randomized, Multicenter, Two-Arm, Open-Label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif® New Formulation From Rebif® (Interferon Beta-1a) With Ibuprofen PRN or as Prophylaxis |
Enrollment: | 120 |
Study Start Date: | June 2007 |
Estimated Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Active Comparator |
Drug: Rebif New Formulation + prophylactically Ibuprofen
Subject receives systematically 400mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44mcg tiw is injected (3 times weekly)
|
2: Active Comparator |
Drug: Rebif New Formulation + ibuprofen PRN
Subjects should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
|
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Female subjects must be neither pregnant nor breast-feeding and must lack childbearing potential, as defined by either:
Exclusion Criteria:
Contraindication to ibuprofen:
France | |||||
Local Medical Information | |||||
Paris, France | |||||
Germany | |||||
Local Medical Information | |||||
Munich, Germany |
EMD Serono |
Study Director: | Sabine Latoure, MD | Merck Serono International S.A., an affiliate of Merck KGaA, Darmstadt, Germany |
Responsible Party: | EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany ( Liz Gedney, Clinical Trial Leader ) |
Study ID Numbers: | 27571 |
First Received: | February 8, 2008 |
Last Updated: | February 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00619307 |
Health Authority: | France: Afssaps - French Health Products Safety Agency; France: Institutional Ethical Committee; Germany: Ethics Commission; Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|